A new “exploratory” report from the Institute for Clinical and Economic Review highlights the lack of information available on US payer decisions regarding formulary placement and utilization management restrictions for prescription drugs, suggesting a new area of focus in the broader push for US payer transparency.
ICER’s first annual “Barriers to Fair Access” assessment of prescription drug coverage policies among US commercial insurers looks at...







